Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
– Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since enrollment began last quarter –
Related news for (FEMY)
- MoBot alert highlights: NASDAQ: CLPS, NASDAQ: PSNL, NASDAQ: IVF, UNK: UVIX, NASDAQ: FEMY (10/16/25 03:00 PM)
- Today’s Top Performers: MoBot’s Market Review 10/16/25 02:00 PM
- MoBot’s Stock Market Highlights – 10/16/25 01:00 PM
- Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
- 24/7 Market News Snapshot 16 October, 2025 – Femasys Inc. Common Stock (NASDAQ:FEMY)